Strategic Partnerships Medlior collaborates with leading pharmaceutical companies and healthcare organizations, evidenced by Boehringer Ingelheim partnership for study design. This indicates a receptiveness to partner-driven RWE, HEOR, and HTA projects, presenting an opportunity to pursue co-development or sponsored research engagements with large pharma and biopharma clients.

RWE and AI Focus Positioned as a pioneer in Real-World Evidence and AI applications for healthcare, Medlior’s value proposition centers on data-driven decision support. Sales opportunities exist in expanding RWE study design, AI-powered analytics, and HTA submissions for clients looking to strengthen market access and payer discussions.

Women-Owned Value As a women-owned, independent consultancy with a collaborative approach, Medlior may appeal to organizations prioritizing diverse suppliers and inclusive leadership. This can be leveraged in procurement conversations, especially with global healthcare entities that emphasize supplier diversity criteria.

Global Health Outcomes With a track record since 2008 and engagements with governmental bodies and major pharma, Medlior has credibility in health technology assessments and policy-informing research. Opportunities exist to expand HTA submissions, regulatory submissions support, and regional health policy research programs.

Growth Signals Recent partnerships and a stated expansion of tools like Real World Radar in 2019 indicate ongoing capability growth and client-demand-driven scaling. This suggests readiness for additional project-based engagements, capacity-enabled services, and potential upsell into full-service HEOR packages for mid-to-large clients.